Study Title

Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Study Details

Description:

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Sponsor:

Central Hospital, Nancy, France

Contacts:

Boursier Caroline, MD

c.boursier@chru-nancy.fr

+33383154276

Véronique ROCH, MSC

v.roch@chru-nancy.fr

+33383154276

Government Study Link:

NCT06614205 - Click here to see study on

ClinicalTrials.gov

Drug Details

177Lu-Dotatate
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • SSTR+
Ligand: Peptides
Chelator: DOTA

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468